T Cells

Dubois' Lupus Erythematosus and Related Syndromes: Eighth Edition

Volumn , Issue , 2013, Pages 96-103

  Crispín, José C ^a   Tsokos, George C ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84901004663     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4377-1893-5.00009-1     Document Type: Chapter

References (120)

1. Crispin JC, Kyttaris VC, Terhorst C, et al. T cells as therapeutic targets in systemic lupus erythematosus. Nat Rev Rheumatol 2010, 6:317-325.
2. Crispin JC, Kyttaris VC, Juang YT, et al. How signaling and gene transcription aberrations dictate the systemic lupus erythematosus T cell phenotype. Trends Immunol 2008, 29:110-115.
3. Vassilopoulos D, Kovacs B, Tsokos GC TCR/CD3 complex-mediated signal transduction pathway in T cells and T cell lines from patients with systemic lupus erythematosus. J Immunol 1995, 155:2269-2281.
4. Juang YT, Peoples C, Kafri R, et al. A systemic lupus erythematosus gene expression array in disease diagnosis and classification: a preliminary report. Lupus 2011, 20:243-249.
5. Shlomchik M, Mascelli M, Shan H, et al. Anti-DNA antibodies from autoimmune mice arise by clonal expansion and somatic mutation. J Exp Med 1990, 171:265-292.
6. Hang L, Theofilopoulos AN, Balderas RS, et al. The effect of thymectomy on lupus-prone mice. J Immunol 1984, 132:1809-1813.
7. Ravirajan CT, Rahman MA, Papadaki L, et al. Genetic, structural and functional properties of an IgG DNA-binding monoclonal antibody from a lupus patient with nephritis. Eur J Immunol 1998, 28:339-350.
8. Grammer AC, Slota R, Fischer R, et al. Abnormal germinal center reactions in systemic lupus erythematosus demonstrated by blockade of CD154-CD40 interactions. J Clin Invest 2003, 112:1506-1520.
9. Kyttaris VC, Wang Y, Juang YT, et al. Increased levels of NF-ATc2 differentially regulate CD154 and IL-2 genes in T cells from patients with systemic lupus erythematosus. J Immunol 2007, 178:1960-1966.
10. Crotty S Follicular helper CD4 T cells (TFH). Annu Rev Immunol 2011, 29:621-663.
11. Vinuesa CG, Cook MC, Angelucci C, et al. A RING-type ubiquitin ligase family member required to repress follicular helper T cells and autoimmunity. Nature 2005, 435:452-458.
12. + regulatory T cells is essential for self tolerance. Nature 2010, 467:328-332.
13. Odegard JM, Marks BR, DiPlacido LD, et al. ICOS-dependent extrafollicular helper T cells elicit IgG production via IL-21 in systemic autoimmunity. J Exp Med 2008, 205:2873-2886.
14. Bubier JA, Sproule TJ, Foreman O, et al. A critical role for IL-21 receptor signaling in the pathogenesis of systemic lupus erythematosus in BXSB-Yaa mice. Proc Natl Acad Sci U S A 2009, 106:1518-1523.
15. Foster AD, Haas M, Puliaeva I, et al. Donor CD8 T cell activation is critical for greater renal disease severity in female chronic graft-vs.-host mice and is associated with increased splenic ICOS(hi) host CD4 T cells and IL-21 expression. Clin Immunol 2010, 136:61-73.
16. Kim HJ, Wang X, Radfar S, et al. CD8+ T regulatory cells express the Ly49 Class I MHC receptor and are defective in autoimmune prone B6-Yaa mice. Proc Natl Acad Sci U S A 2011, 108:2010-2015.
17. Simpson N, Gatenby PA, Wilson A, et al. Expansion of circulating T cells resembling follicular helper T cells is a fixed phenotype that identifies a subset of severe systemic lupus erythematosus. Arthritis Rheum 2010, 62:234-244.
18. Shlomchik MJ, Craft JE, Mamula MJ From T to B and back again: positive feedback in systemic autoimmune disease. Nat Rev Immunol 2001, 1:147-153.
19. Llorente L, Richaud-Patin Y, Couderc J, et al. Dysregulation of interleukin-10 production in relatives of patients with systemic lupus erythematosus. Arthritis Rheum 1997, 40:1429-1435.
20. Llorente L, Zou W, Levy Y, et al. Role of interleukin 10 in the B lymphocyte hyperactivity and autoantibody production of human systemic lupus erythematosus. J Exp Med 1995, 181:839-844.
21. Ishida H, Muchamuel T, Sakaguchi S, et al. Continuous administration of anti-interleukin 10 antibodies delays onset of autoimmunity in NZB/W F1 mice. J Exp Med 1994, 179:305-310.
22. Llorente L, Richaud-Patin Y, Garcia-Padilla C, et al. Clinical and biologic effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythematosus. Arthritis Rheum 2000, 43:1790-1800.
23. Hsieh C, Chang A, Brandt D, et al. Predicting outcomes of lupus nephritis with tubulointerstitial inflammation and scarring. Arthritis Care Res (Hoboken) 2011, 63:865-874.
24. Korn T, Bettelli E, Oukka M, et al. IL-17 and Th17 Cells. Annu Rev Immunol 2009, 27:485-517.
25. Doreau A, Belot A, Bastid J, et al. Interleukin 17 acts in synergy with B cell-activating factor to influence B cell biology and the pathophysiology of systemic lupus erythematosus. Nat Immunol 2009, 10:778-785.
26. Crispin JC, Oukka M, Bayliss G, et al. Expanded double negative T cells in patients with systemic lupus erythematosus produce IL-17 and infiltrate the kidneys. J Immunol 2008, 181:8761-8766.
27. Shah K, Lee WW, Lee SH, et al. Dysregulated balance of Th17 and Th1 cells in systemic lupus erythematosus. Arthritis Res Ther 2010, 12:R53-R63.
28. Kang HK, Liu M, Datta SK Low-dose peptide tolerance therapy of lupus generates plasmacytoid dendritic cells that cause expansion of autoantigen-specific regulatory T cells and contraction of inflammatory Th17 cells. J Immunol 2007, 178:7849-7858.
29. Zhang Z, Kyttaris VC, Tsokos GC The role of IL-23/IL-17 axis in lupus nephritis. J Immunol 2009, 183:3160-3169.
30. Wu HY, Quintana FJ, Weiner HL Nasal anti-CD3 antibody ameliorates lupus by inducing an IL-10-secreting CD4+. J Immunol 2008, 181:6038-6050.
31. Linker-Israeli M, Deans RJ, Wallace DJ, et al. Elevated levels of endogenous IL-6 in systemic lupus erythematosus. A putative role in pathogenesis. J Immunol 1991, 147:117-123.
32. Alcocer-Varela J, Alarcon-Segovia D Decreased production of and response to interleukin-2 by cultured lymphocytes from patients with systemic lupus erythematosus. J Clin Invest 1982, 69:1388-1392.
33. Yang XP, Ghoreschi K, Steward-Tharp SM, et al. Opposing regulation of the locus encoding IL-17 through direct, reciprocal actions of STAT3 and STAT5. Nat Immunol 2011, 12:247-254.
34. Tsokos GC, Boumpas DT, Smith PL, et al. Deficient gamma-interferon production in patients with systemic lupus erythematosus. Arthritis Rheum 1986, 29:1210-1215.
35. Neighbour PA, Grayzel AI Interferon production of vitro by leucocytes from patients with systemic lupus erythematosus and rheumatoid arthritis. Clin Exp Immunol 1981, 45:576-582.
36. Harigai M, Kawamoto M, Hara M, et al. Excessive production of IFN-gamma in patients with systemic lupus erythematosus and its contribution to induction of B lymphocyte stimulator/B cell-activating factor/TNF ligand superfamily-13B. J Immunol 2008, 181:2211-2219.
37. Basu D, Liu Y, Wu A, et al. Stimulatory and inhibitory killer Ig-like receptor molecules are expressed and functional on lupus T cells. J Immunol 2009, 183:3481-3487.
38. Uhm WS, Na K, Song GW, et al. Cytokine balance in kidney tissue from lupus nephritis patients. Rheumatology (Oxford) 2003, 42:935-938.
39. Chan RW, Lai FM, Li EK, et al. Intrarenal cytokine gene expression in lupus nephritis. Ann Rheum Dis 2007, 66:886-892.
40. Haas C, Ryffel B, Le HM IFN-gamma receptor deletion prevents autoantibody production and glomerulonephritis in lupus-prone (NZB x NZW)F1 mice. J Immunol 1998, 160:3713-3718.
41. Balomenos D, Rumold R, Theofilopoulos AN Interferon-gamma is required for lupus-like disease and lymphoaccumulation in MRL-lpr mice. J Clin Invest 1998, 101:364-371.
42. Li Y, Harada T, Juang YT, et al. Phosphorylated ERM is responsible for increased T cell polarization, adhesion, and migration in patients with systemic lupus erythematosus. J Immunol 2007, 178:1938-1947.
43. Estess P, DeGrendele HC, Pascual V, et al. Functional activation of lymphocyte CD44 in peripheral blood is a marker of autoimmune disease activity. J Clin Invest 1998, 102:1173-1182.
44. Crispin JC, Keenan BT, Finnell MD, et al. Expression of CD44 variant isoforms CD44v3 and CD44v6 is increased on T cells from patients with systemic lupus erythematosus and is correlated with disease activity. Arthritis Rheum 2010, 62:1431-1437.
45. Cohen RA, Bayliss G, Crispin JC, et al. T cells and in situ cryoglobulin deposition in the pathogenesis of lupus nephritis. Clin Immunol 2008, 128:1-7.
46. Viallard JF, Bloch-Michel C, Neau-Cransac M, et al. HLA-DR expression on lymphocyte subsets as a marker of disease activity in patients with systemic lupus erythematosus. Clin Exp Immunol 2001, 125:485-491.
47. Blanco P, Pitard V, Viallard JF, et al. Increase in activated CD8+ T lymphocytes expressing perforin and granzyme B correlates with disease activity in patients with systemic lupus erythematosus. Arthritis Rheum 2005, 52:201-211.
48. Couzi L, Merville P, Deminiere C, et al. Predominance of CD8+ T lymphocytes among periglomerular infiltrating cells and link to the prognosis of class III and class IV lupus nephritis. Arthritis Rheum 2007, 56:2362-2370.
49. Stohl W Impaired polyclonal T cell cytolytic activity. A possible risk factor for systemic lupus erythematosus. Arthritis Rheum 1995, 38:506-516.
50. Shivakumar S, Tsokos GC, Datta SK T cell receptor alpha/beta expressing double-negative (CD4-/CD8-) and CD4+ T helper cells in humans augment the production of pathogenic anti-DNA autoantibodies associated with lupus nephritis. J Immunol 1989, 143:103-112.
51. Sieling PA, Porcelli SA, Duong BT, et al. Human double-negative T cells in systemic lupus erythematosus provide help for IgG and are restricted by CD1c. J Immunol 2000, 165:5338-5344.
52. + T cells and display an inflammatory effector phenotype. J Immunol 2009, 183:4675-4681.
53. Sakaguchi S, Yamaguchi T, Nomura T, et al. Regulatory T cells and immune tolerance. Cell 2008, 133:775-787.
54. Le BS, Geha RS IPEX and the role of Foxp3 in the development and function of human Tregs. J Clin Invest 2006, 116:1473-1475.
55. Crispin JC, Martinez A, Alcocer-Varela J Quantification of regulatory T cells in patients with systemic lupus erythematosus. J Autoimmun 2003, 21:273-276.
56. Miyara M, Amoura Z, Parizot C, et al. Global natural regulatory T cell depletion in active systemic lupus erythematosus. J Immunol 2005, 175:8392-8400.
57. Lee JH, Wang LC, Lin YT, et al. Inverse correlation between CD4+ regulatory T-cell population and autoantibody levels in paediatric patients with systemic lupus erythematosus. Immunology 2006, 117:280-286.
58. high T regulatory cell function in patients with active systemic lupus erythematosus. J Immunol 2007, 178:2579-2588.
59. Bonelli M, Savitskaya A, von DK, et al. Quantitative and qualitative deficiencies of regulatory T cells in patients with systemic lupus erythematosus (SLE). Int Immunol 2008, 20:861-868.
60. Vargas-Rojas MI, Crispin JC, Richaud-Patin Y, et al. Quantitative and qualitative normal regulatory T cells are not capable of inducing suppression in SLE patients due to T-cell resistance. Lupus 2008, 17:289-294.
61. Monk CR, Spachidou M, Rovis F, et al. MRL/Mp CD4+CD25- T cells show reduced sensitivity to suppression by CD4+CD25+ regulatory T cells in vitro: a novel defect of T cell regulation in systemic lupus erythematosus. Arthritis Rheum 2005, 52:1180-1184.
62. Zhang L, Bertucci AM, Ramsey-Goldman R, et al. Regulatory T cell (Treg) subsets return in patients with refractory lupus following stem cell transplantation, and TGF-beta-producing CD8+ Treg cells are associated with immunological remission of lupus. J Immunol 2009, 183:6346-6358.
63. Anderson MS, Su MA Aire and T cell development. Curr Opin Immunol 2011, 23:198-206.
64. Andreassen K, Bendiksen S, Kjeldsen E, et al. T cell autoimmunity to histones and nucleosomes is a latent property of the normal immune system. Arthritis Rheum 2002, 46:1270-1281.
65. Voll RE, Roth EA, Girkontaite I, et al. Histone-specific Th0 and Th1 clones derived from systemic lupus erythematosus patients induce double-stranded DNA antibody production. Arthritis Rheum 1997, 40:2162-2171.
66. Kotzin BL, Kappler JW, Marrack PC, et al. T cell tolerance to self antigens in New Zealand hybrid mice with lupus-like disease. J Immunol 1989, 143:89-94.
67. Herron LR, Eisenberg RA, Roper E, et al. Selection of the T cell receptor repertoire in Lpr mice. J Immunol 1993, 151:3450-3459.
68. Fatenejad S, Peng SL, Disorbo O, et al. Central T cell tolerance in lupus-prone mice: influence of autoimmune background and the lpr mutation. J Immunol 1998, 161:6427-6432.
69. Harley IT, Kaufman KM, Langefeld CD, et al. Genetic susceptibility to SLE: new insights from fine mapping and genome-wide association studies. Nat Rev Genet 2009, 10:285-290.
70. Liossis SN, Ding XZ, Dennis GJ, et al. Altered pattern of TCR/CD3-mediated protein-tyrosyl phosphorylation in T cells from patients with systemic lupus erythematosus. Deficient expression of the T cell receptor zeta chain. J Clin Invest 1998, 101:1448-1457.
71. Enyedy EJ, Nambiar MP, Liossis SN, et al. Fc epsilon receptor type I gamma chain replaces the deficient T cell receptor zeta chain in T cells of patients with systemic lupus erythematosus. Arthritis Rheum 2001, 44:1114-1121.
72. Krishnan S, Juang YT, Chowdhury B, et al. Differential expression and molecular associations of Syk in systemic lupus erythematosus T cells. J Immunol 2008, 181:8145-8152.
73. Tsokos GC, Nambiar MP, Tenbrock K, et al. Rewiring the T-cell: signaling defects and novel prospects for the treatment of SLE. Trends Immunol 2003, 24:259-263.
74. Juang YT, Tenbrock K, Nambiar MP, et al. Defective production of functional 98-kDa form of Elf-1 is responsible for the decreased expression of TCR zeta-chain in patients with systemic lupus erythematosus. J Immunol 2002, 169:6048-6055.
75. Juang YT, Wang Y, Jiang G, et al. PP2A dephosphorylates Elf-1 and determines the expression of CD3zeta and FcRgamma in human systemic lupus erythematosus T cells. J Immunol 2008, 181:3658-3664.
76. Tenbrock K, Kyttaris VC, Ahlmann M, et al. The cyclic AMP response element modulator regulates transcription of the TCR zeta-chain. J Immunol 2005, 175:5975-5980.
77. Moulton VR, Kyttaris VC, Juang YT, et al. The RNA-stabilizing protein HuR regulates the expression of zeta chain of the human T cell receptor-associated CD3 complex. J Biol Chem 2008, 283:20037-20044.
78. Chowdhury B, Tsokos CG, Krishnan S, et al. Decreased stability and translation of T cell receptor zeta mRNA with an alternatively spliced 3'-untranslated region contribute to zeta chain down-regulation in patients with systemic lupus erythematosus. J Biol Chem 2005, 280:18959-18966.
79. Krishnan S, Kiang JG, Fisher CU, et al. Increased caspase-3 expression and activity contribute to reduced CD3zeta expression in systemic lupus erythematosus T cells. J Immunol 2005, 175:3417-3423.
80. Jury EC, Kabouridis PS, Flores-Borja F, et al. Altered lipid raft-associated signaling and ganglioside expression in T lymphocytes from patients with systemic lupus erythematosus. J Clin Invest 2004, 113:1176-1187.
81. Krishnan S, Nambiar MP, Warke VG, et al. Alterations in lipid raft composition and dynamics contribute to abnormal T cell responses in systemic lupus erythematosus. J Immunol 2004, 172:7821-7831.
82. Jury EC, Isenberg DA, Mauri C, et al. Atorvastatin restores Lck expression and lipid raft-associated signaling in T cells from patients with systemic lupus erythematosus. J Immunol 2006, 177:7416-7422.
83. Deng GM, Tsokos GC Cholera toxin B accelerates disease progression in lupus-prone mice by promoting lipid raft aggregation. J Immunol 2008, 181:4019-4026.
84. Cedeno S, Cifarelli DF, Blasini AM, et al. Defective activity of ERK-1 and ERK-2 mitogen-activated protein kinases in peripheral blood T lymphocytes from patients with systemic lupus erythematosus: potential role of altered coupling of Ras guanine nucleotide exchange factor hSos to adapter protein Grb2 in lupus T cells. Clin Immunol 2003, 106:41-49.
85. Mor A, Philips MR, Pillinger MH The role of Ras signaling in lupus T lymphocytes: biology and pathogenesis. Clin Immunol 2007, 125:215-223.
86. Rui L, Vinuesa CG, Blasioli J, et al. Resistance to CpG DNA-induced autoimmunity through tolerogenic B cell antigen receptor ERK signaling. Nat Immunol 2003, 4:594-600.
87. Layer K, Lin G, Nencioni A, et al. Autoimmunity as the consequence of a spontaneous mutation in Rasgrp1. Immunity 2003, 19:243-255.
88. Gorelik G, Fang JY, Wu A, et al. Impaired T cell protein kinase C delta activation decreases ERK pathway signaling in idiopathic and hydralazine-induced lupus. J Immunol 2007, 179:5553-5563.
89. Mandler R, Birch RE, Polmar SH, et al. Abnormal adenosine-induced immunosuppression and cAMP metabolism in T lymphocytes of patients with systemic lupus erythematosus. Proc Natl Acad Sci U S A 1982, 79:7542-7546.
90. Kammer GM, Khan IU, Malemud CJ Deficient type I protein kinase A isozyme activity in systemic lupus erythematosus T lymphocytes. J Clin Invest 1994, 94:422-430.
91. Tada Y, Nagasawa K, Yamauchi Y, et al. A defect in the protein kinase C system in T cells from patients with systemic lupus erythematosus. Clin Immunol Immunopathol 1991, 60:220-231.
92. Matache C, Stefanescu M, Onu A, et al. p56lck activity and expression in peripheral blood lymphocytes from patients with systemic lupus erythematosus. Autoimmunity 1999, 29:111-120.
93. Grolleau A, Kaplan MJ, Hanash SM, et al. Impaired translational response and increased protein kinase PKR expression in T cells from lupus patients. J Clin Invest 2000, 106:1561-1568.
94. Niculescu F, Nguyen P, Niculescu T, et al. Pathogenic T cells in murine lupus exhibit spontaneous signaling activity through phosphatidylinositol 3-kinase and mitogen-activated protein kinase pathways. Arthritis Rheum 2003, 48:1071-1079.
95. Barber DF, Bartolome A, Hernandez C, et al. PI3Kgamma inhibition blocks glomerulonephritis and extends lifespan in a mouse model of systemic lupus. Nat Med 2005, 11:933-935.
96. Barber DF, Bartolome A, Hernandez C, et al. Class IB-phosphatidylinositol 3-kinase (PI3K) deficiency ameliorates IA-PI3K-induced systemic lupus but not T cell invasion. J Immunol 2006, 176:589-593.
97. Yi Y, McNerney M, Datta SK Regulatory defects in Cbl and mitogen-activated protein kinase (extracellular signal-related kinase) pathways cause persistent hyperexpression of CD40 ligand in human lupus T cells. J Immunol 2000, 165:6627-6634.
98. Tenbrock K, Tsokos GC Transcriptional regulation of interleukin 2 in SLE T cells. Int Rev Immunol 2004, 23:333-345.
99. Solomou EE, Juang YT, Gourley MF, et al. Molecular basis of deficient IL-2 production in T cells from patients with systemic lupus erythematosus. J Immunol 2001, 166:4216-4222.
100. Kyttaris VC, Juang YT, Tenbrock K, et al. Cyclic adenosine 5'-monophosphate response element modulator is responsible for the decreased expression of c-fos and activator protein-1 binding in T cells from patients with systemic lupus erythematosus. J Immunol 2004, 173:3557-3563.
101. Ahlmann M, Varga G, Sturm K, et al. The cyclic AMP response element modulator {alpha} suppresses CD86 expression and APC function. J Immunol 2009, 182:4167-4174.
102. Juang YT, Wang Y, Solomou EE, et al. Systemic lupus erythematosus serum IgG increases CREM binding to the IL-2 promoter and suppresses IL-2 production through CaMKIV. J Clin Invest 2005, 115:996-1005.
103. Katsiari CG, Kyttaris VC, Juang YT, et al. Protein phosphatase 2A is a negative regulator of IL-2 production in patients with systemic lupus erythematosus. J Clin Invest 2005, 115:3193-3204.
104. Wadzinski BE, Wheat WH, Jaspers S, et al. Nuclear protein phosphatase 2A dephosphorylates protein kinase A-phosphorylated CREB and regulates CREB transcriptional stimulation. Mol Cell Biol 1993, 13:2822-2834.
105. Richardson B, Scheinbart L, Strahler J, et al. Evidence for impaired T cell DNA methylation in systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum 1990, 33:1665-1673.
106. Scheinbart LS, Johnson MA, Gross LA, et al. Procainamide inhibits DNA methyltransferase in a human T cell line. J Rheumatol 1991, 18:530-534.
107. Deng C, Lu Q, Zhang Z, et al. Hydralazine may induce autoimmunity by inhibiting extracellular signal-regulated kinase pathway signaling. Arthritis Rheum 2003, 48:746-756.
108. Deng C, Kaplan MJ, Yang J, et al. Decreased Ras-mitogen-activated protein kinase signaling may cause DNA hypomethylation in T lymphocytes from lupus patients. Arthritis Rheum 2001, 44:397-407.
109. Sawalha AH, Jeffries M, Webb R, et al. Defective T-cell ERK signaling induces interferon-regulated gene expression and overexpression of methylation-sensitive genes similar to lupus patients. Genes Immun 2008, 9:368-378.
110. Tenbrock K, Juang YT, Leukert N, et al. The transcriptional repressor cAMP response element modulator alpha interacts with histone deacetylase 1 to repress promoter activity. J Immunol 2006, 177:6159-6164.
111. Martin M, Potente M, Janssens V, et al. Protein phosphatase 2A controls the activity of histone deacetylase 7 during T cell apoptosis and angiogenesis. Proc Natl Acad Sci U S A 2008, 105:4727-4732.
112. Mishra N, Brown DR, Olorenshaw IM, et al. Trichostatin A reverses skewed expression of CD154, interleukin-10, and interferon-gamma gene and protein expression in lupus T cells. Proc Natl Acad Sci U S A 2001, 98:2628-2633.
113. Gergely P, Grossman C, Niland B, et al. Mitochondrial hyperpolarization and ATP depletion in patients with systemic lupus erythematosus. Arthritis Rheum 2002, 46:175-190.
114. Nagy G, Barcza M, Gonchoroff N, et al. Nitric oxide-dependent mitochondrial biogenesis generates Ca2+ signaling profile of lupus T cells. J Immunol 2004, 173:3676-3683.
115. Fernandez D, Bonilla E, Mirza N, et al. Rapamycin reduces disease activity and normalizes T cell activation-induced calcium fluxing in patients with systemic lupus erythematosus. Arthritis Rheum 2006, 54:2983-2988.
116. Emlen W, Niebur J, Kadera R Accelerated in vitro apoptosis of lymphocytes from patients with systemic lupus erythematosus. J Immunol 1994, 152:3685-3692.
117. Kovacs B, Vassilopoulos D, Vogelgesang SA, et al. Defective CD3-mediated cell death in activated T cells from patients with systemic lupus erythematosus: role of decreased intracellular TNF-alpha. Clin Immunol Immunopathol 1996, 81:293-302.
118. Xu L, Zhang L, Yi Y, et al. Human lupus T cells resist inactivation and escape death by upregulating COX-2. Nat Med 2004, 10:411-415.
119. Crispin JC, Apostolidis SA, Finnell MI, et al. Induction of PP2A Bβ, a regulator of IL-2 deprivation-induced T-cell apoptosis, is deficient in systemic lupus erythematosus. Proc Natl Acad Sci U S A 2011, 108(30):12443-12448.
120. Cohen PL, Eisenberg RA Lpr and gld: single gene models of systemic autoimmunity and lymphoproliferative disease. Annu Rev Immunol 1991, 9:243-269.